Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 16/20 | 0.53 |
| ▸ | CTSS | P25774 | 13/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571484 | 0.92 | CTSL (0.56) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3594594 | 0.87 | CTSL (0.56) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3601032 | 0.82 | CTSL (0.63) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3603514 | 0.82 | CTSL (0.68) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3591605 | 0.81 | CTSL (0.81) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3585874 | 0.80 | CTSL (0.57) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL5571480 | 0.79 | CTSL (0.58) | CTSLCTSSKCNH2CTSK | |
| SCHEMBL3585558 | 0.77 | CTSL (0.70) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3599719 | 0.77 | CTSL (0.62) | CTSLCTSSKCNH2CTSKGPR119 | |
| SCHEMBL3596107 | 0.77 | CTSL (0.82) | CTSLCTSSKCNH2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CTSL 9/4885CTSS 1/4885KCNH2 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.